review Open AccessTop 1% cited

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

BMC Cancer · 2008 · Vol. 8(1) · pp. 82–82

Volker Heinemann✉Stefan BoeckAxel HinkeRoberto Labianca(Azienda Ospedaliero Universitaria Ospedali Riuniti)Christophe Louvet(Hôpital Saint-Antoine)

View via DOI Full-text PDF

Abstract

The meta-analysis of randomized trials indicated a significant survival benefit when GEM was either combined with platinum analogs or fluoropyrimidines. Based on a preliminary subgroup analysis (representing 38% of all patients included in this meta-analysis), pancreatic cancer patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas patients with a poor PS seem to have no survival benefit from combination chemotherapy.

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Lung Cancer Treatments and MutationsMedicineGemcitabineInternal medicinePemetrexedIrinotecanHazard ratioOncologyRandomized controlled trialPancreatic cancerChemotherapy

MeSH terms

OxaliplatinGemcitabineAminoacridinesAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineFemaleHumansMaleOrganoplatinum CompoundsPancreatic NeoplasmsSurvival AnalysisRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic